IRIS
TASSONE, PIERFRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.219
AS - Asia 4.254
EU - Europa 2.714
SA - Sud America 1.242
AF - Africa 95
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 19
Totale 14.568
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.913
SG - Singapore 1.765
IT - Italia 1.236
CN - Cina 1.041
BR - Brasile 954
IN - India 586
VN - Vietnam 417
SE - Svezia 405
GB - Regno Unito 346
DE - Germania 269
CA - Canada 236
AR - Argentina 102
FI - Finlandia 102
HK - Hong Kong 71
ID - Indonesia 69
EC - Ecuador 58
NL - Olanda 55
MX - Messico 46
BD - Bangladesh 44
FR - Francia 42
RU - Federazione Russa 41
RO - Romania 36
ES - Italia 35
CO - Colombia 33
UA - Ucraina 33
PK - Pakistan 32
IQ - Iraq 31
ZA - Sudafrica 29
JP - Giappone 28
PY - Paraguay 26
JO - Giordania 24
CL - Cile 23
EU - Europa 22
PL - Polonia 22
TR - Turchia 22
IR - Iran 20
PE - Perù 19
SA - Arabia Saudita 19
EG - Egitto 18
VE - Venezuela 18
CZ - Repubblica Ceca 17
LT - Lituania 16
AT - Austria 14
AE - Emirati Arabi Uniti 13
AU - Australia 12
MA - Marocco 11
KR - Corea 10
PT - Portogallo 9
TN - Tunisia 9
UY - Uruguay 8
ET - Etiopia 7
IE - Irlanda 7
MY - Malesia 7
NG - Nigeria 7
DZ - Algeria 6
EE - Estonia 6
LB - Libano 6
UZ - Uzbekistan 6
BG - Bulgaria 5
CY - Cipro 5
GT - Guatemala 5
HN - Honduras 5
DO - Repubblica Dominicana 4
IL - Israele 4
KE - Kenya 4
KZ - Kazakistan 4
NZ - Nuova Zelanda 4
PH - Filippine 4
PS - Palestinian Territory 4
TW - Taiwan 4
AZ - Azerbaigian 3
CH - Svizzera 3
HU - Ungheria 3
LK - Sri Lanka 3
NP - Nepal 3
PA - Panama 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
GR - Grecia 2
HR - Croazia 2
KI - Kiribati 2
KW - Kuwait 2
OM - Oman 2
SN - Senegal 2
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
CV - Capo Verde 1
DK - Danimarca 1
GE - Georgia 1
GM - Gambi 1
JM - Giamaica 1
NI - Nicaragua 1
NR - Nauru 1
PR - Porto Rico 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 14.565
Salva come PNG Salva come JPEG
Città #
Chandler 906
Singapore 749
Dallas 505
Santa Clara 457
Bengaluru 428
Hefei 428
Milan 388
Lawrence 383
Princeton 383
Chicago 269
London 249
Wilmington 224
Ashburn 221
Munich 209
Ottawa 165
Ho Chi Minh City 163
Catanzaro 153
Beijing 150
Des Moines 111
Boardman 84
Hanoi 84
São Paulo 80
Turku 73
Los Angeles 69
Hong Kong 59
New York 53
Shanghai 48
Rome 45
Guangzhou 41
Pune 40
Rio de Janeiro 38
Norwalk 32
San Francisco 31
The Dalles 31
Brooklyn 30
Redwood City 30
Helsinki 29
Naples 28
Redmond 28
Council Bluffs 26
Montreal 22
Chennai 20
Warsaw 20
Columbus 19
Parma 19
Quito 19
Boston 18
Stockholm 18
Amman 16
Biên Hòa 16
Da Nang 16
Manchester 16
Phoenix 16
Salvador 16
San Nicola Manfredi 16
Tokyo 16
Atlanta 15
Denver 15
Charlotte 14
Olomouc 14
West Jordan 14
Guayaquil 13
Haiphong 13
Horia 13
Mexico City 13
Mountain View 13
Porto Alegre 13
Reggio Calabria 13
Amsterdam 12
Carbonia 12
Curitiba 12
Delhi 12
Palermo 12
Recife 12
Thái Bình 12
Timisoara 12
Vallefiorita 12
Washington 12
Augusta 11
Baghdad 11
Brasília 11
Buenos Aires 11
Campinas 11
Cosenza 11
Dhaka 11
Hanover 11
Johannesburg 11
Madrid 10
Seattle 10
Thái Nguyên 10
Zhengzhou 10
Ankara 9
Aversa 9
Belo Horizonte 9
Bogotá 9
Duque de Caxias 9
Fortaleza 9
Jakarta 9
Jiaxing 9
Las Vegas 9
Totale 8.306
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 400
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 112
miR-22 suppresses DNA ligase III addiction in multiple myeloma 92
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 91
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 81
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 78
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 75
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 73
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 69
A 5 ' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells 67
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 65
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 65
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 65
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer 65
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 65
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 65
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 65
Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43 64
Pyrrolo[2′,3′:3,4]cyclohepta[1,2- d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types 64
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 63
277 POSTER An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 62
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 60
Associazione di antagonisti di IL-6 e farmaci anti-proliferativi (depositato il 10.3.2005 n. RM2005A000103) 60
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 60
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 60
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 60
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 59
Differential microRNAs expression profile in coronary thrombi from patients with no-reflow after primary PCI 57
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 57
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 56
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 55
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 55
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 55
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 55
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 54
A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells 54
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 54
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 54
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 54
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 54
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 54
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 53
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 53
miR-221/222 inhibitors for the treatment of multiple myeloma 53
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 53
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 53
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 53
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 52
Mir-34: a new weapon against cancer? 51
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 51
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 50
Liposomes containing zoledronic acid: A new opportunity against cancer 50
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 50
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 50
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 50
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 49
Biochemical modification of an Interleukin-6 antagonist to target myeloma cells in the bone marrow microenvironment 49
Fetal ontogeny and tumor expression of the early thymic antigen UN1 49
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 49
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 49
PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle 48
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 48
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 48
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 48
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 48
Anti-myeloma activity of miR-125 mimics 48
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 47
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 47
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 47
Modulation of Exosomal microRNA in patients with severe Aortic Stenosis after Transcatheter Aortic Valve Implantation (TAVI) 47
HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells 47
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells 47
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 46
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 46
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 46
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 45
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 45
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 45
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 45
Genes specifically expressed during early stages of haemopoietic differentiation detected by DDRT-PCR. 45
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 45
Mir-221/222 are promising targets for innovative anticancer therapy 44
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia 44
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 44
Transcriptional regulation of the mismatch repair gene hMLH1 44
Editorial: New approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta) 44
Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma 44
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 44
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 44
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 44
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 44
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 44
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates 44
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 44
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 44
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 43
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 43
[Extended subcutaneous mastectomy. A new type of operation in non-destructive surgery of breast neoplasms]. FT La mastectomia sottocutanea allargata. Un nuovo tipo d'intervento nella chirurgia non demolitiva della neoplasia mammaria. 43
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 43
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 43
Totale 5.749
Salva come PNG Salva come JPEG
Categoria #
all - tutte 174.727
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 174.727
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021433 0 0 0 23 63 53 33 26 73 82 65 15
2021/20221.151 27 6 17 333 87 20 29 249 114 97 149 23
2022/20232.838 787 108 110 204 299 234 23 198 425 171 228 51
2023/20241.557 347 158 127 110 104 379 45 61 13 51 65 97
2024/20254.484 615 274 203 134 251 564 126 163 510 266 448 930
2025/20263.999 454 966 1.028 1.551 0 0 0 0 0 0 0 0
Totale 14.895